Association of the ADIPOQ rs17360539 and rs266729 polymorphisms with type 2 diabetes: a meta-analysis

Mol Cell Endocrinol. 2010 Aug 30;325(1-2):78-83. doi: 10.1016/j.mce.2010.05.007. Epub 2010 May 24.

Abstract

Published data on the association between ADIPOQ polymorphisms and type 2 diabetes are inconsistent. The present meta-analysis was performed to clarify the role of polymorphisms in proximal promoter region of ADIPOQ (rs17360539 and rs266729) in type 2 diabetes. The MEDLINE, EMBASE and Science Citation Index Expanded database were searched for eligible studies. Odd ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. The pooled ORs were performed for per-allele model (A/a) and others genetic models. A total of 10267 T2DM patients and 12837 controls was included in the meta-analysis. Overall the -11377G allele had an 8% elevated risk of T2DM compared to -11377C allele in all subjects (P=0.034, OR=1.08, 95% CI 1.01-1.15). The -11391A allele showed no significant effect on T2DM risk in all subjects (P=0.240, OR=1.10, 95% CI 0.94-1.29) compared to -11391G allele. In the subgroup analyses by ethnicity, -11391A allele increased T2DM risk in European population (P=0.046, OR=1.09, 95% CI 1.00-1.09). In conclusion, the accumulated evidence suggested that the ADIPOQ -11377G allele is a low-penetrant risk factor for developing type 2 diabetes, but -11391A is a risk factor only in European Caucasians.

Publication types

  • Meta-Analysis
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / genetics
  • Alleles
  • Case-Control Studies
  • Diabetes Mellitus, Type 2 / genetics*
  • European Continental Ancestry Group
  • Genetic Predisposition to Disease
  • Genome-Wide Association Study
  • Humans
  • Polymorphism, Single Nucleotide* / physiology
  • Risk Factors
  • United States

Substances

  • ADIPOQ protein, human
  • Adiponectin